Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Retained Earnings (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Retained Earnings for 8 consecutive years, with -$353.2 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 2207912.5% to -$353.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$353.2 million through Dec 2025, down 2207912.5% year-over-year, with the annual reading at -$353.2 million for FY2025, 2207912.5% down from the prior year.
  • Retained Earnings for Q4 2025 was -$353.2 million at Whitehawk Therapeutics, down from -$330.0 million in the prior quarter.
  • The five-year high for Retained Earnings was $16000.0 in Q4 2024, with the low at -$353.2 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$188.8 million, with a median of -$182.0 million recorded in 2022.
  • The sharpest move saw Retained Earnings soared 100.01% in 2024, then crashed 2207912.5% in 2025.
  • Over 5 years, Retained Earnings stood at -$142.7 million in 2021, then surged by 99.92% to -$115000.0 in 2022, then crashed by 233780.87% to -$269.0 million in 2023, then skyrocketed by 100.01% to $16000.0 in 2024, then plummeted by 2207912.5% to -$353.2 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$353.2 million, -$330.0 million, and -$312.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.